CRC Research Update — June 09, 2026
Today's colorectal cancer research highlights
liver-mets
A collection of 11 issues
CRC Research Finding
Skip to content
The CRC Digest
◇ Single-cell analysis identifies epithelial cell fate signature predicting liver metastasis risk
Researchers integrated single-cell RNA sequencing of paired liver metastasis tissues to define an epithelial cell fate gene signature, then projected it onto 433 primary CRC cases to establish a predictive model for liver
CRC Research Update — June 07, 2026
Today's colorectal cancer research highlights
CRC Research Update — June 01, 2026
Today's colorectal cancer research highlights
This Week in CRC Research — May 31, 2026
Weekly colorectal cancer research intelligence
ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases
Skip to content
The CRC Digest
◆ TRIAL DATA
ABFOLFOX neoadjuvant therapy studied in unresectable liver metastases — Genome Medicine
A study examined neoadjuvant ABFOLFOX (atezolizumab, bevacizumab, leucovorin, 5-fluorouracil, and oxaliplatin) in patients with unresectable colorectal liver metastases. The research explored molecular dynamics of tumor ecosystems and their impact on treatment outcomes.
CRC Research Update — May 29, 2026
Today's colorectal cancer research highlights
CRC Research Update — May 12, 2026
Today's colorectal cancer research highlights
CRC Research Update — April 20, 2026
Today's colorectal cancer research highlights
Blood-Based ctDNA Testing May Help Monitor for Cancer Return After Surgery
Skip to content
The CRC Digest
Blood-Based ctDNA Testing May Help Monitor for Cancer Return After Surgery
Meta-analysis supports use of circulating tumor DNA as a biomarker to detect recurrence risk in patients who had liver metastases surgically removed. (Clinical Colorectal Cancer)
This content is informational only and does not